Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that finasteride treatment was effective for male pattern alopecia and that hair loss significantly impacted patients' quality of life and psychological well-being.

This study found that increased Bcl-2 protein expression after DPCP treatment was associated with hair regrowth in alopecia areata patients, suggesting its role in inhibiting apoptosis.

In this study, DOP treatment improved hair regrowth in androgenetic alopecia by altering local steroid metabolism and follicular morphology.

This study found that adjusting the polymer gel composition can create a more consistent release profile of finasteride with reduced initial burst release, enhancing patient compliance through in situ polymer precipitation.

This abstract discusses finasteride and dutasteride's mechanisms in treating androgenetic alopecia and notes FDA approval for finasteride, but reports no new clinical results.

This report describes a woman with borderline lepromatous leprosy who developed a serious skin reaction to dapsone; she recovered quickly after stopping dapsone and receiving corticosteroids.

This case report describes a unique instance of IgG/IgA pemphigus in a Chinese woman, highlighting its distinct clinical and immunopathologic characteristics, including successful management with dapsone and prednisolone.

This study found that nano-sized lipid particles improved the skin accumulation and retention of dexamethasone compared to a base cream, suggesting potential benefits for inflammatory skin disease treatment.

This paper describes a new scalable synthesis method for Dutasteride, highlighting its potential for large-scale commercial production.

This study found that para-phenylenediamine induces cytotoxic effects in normal human hair dermal papilla cells by altering microRNA expression and causing cell death, cell cycle arrest, and oxidative stress.

This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.

This case report describes two postmenopausal women with Parkinson's disease who experienced reversible hair loss after using the dopamine agonists pramipexole and ropinirole.

This study found that using a palmitoylated peptide, Pal-MPAPO, delivered through hydrogel microneedles effectively promoted hair regrowth in mice with efficacy comparable to minoxidil, while requiring less frequent application.

This study found that the film-trigger applicator system enhanced drug delivery efficiency and skin penetration of dissolving microneedles compared to traditional patch systems in both lab and animal models.

This study investigated the use of dissolving microneedle patches to improve the skin-lightening effects of alpha-arbutin and resveratrol, finding that the patches enhanced intradermal delivery and slightly decreased the melanin index without affecting skin hydration or causing irritation over 24 hours.

This study reports that two oral hormonal agents, dimethandrolone undecanoate and 11β-methylnortestosterone dodecylcarbonate, may effectively suppress hormones to contraceptive levels in men with mild side effects, though longer-term trials are required to confirm their safety and efficacy.

This study found that DHEA along with osteogenic induction medium significantly promotes the osteogenic differentiation and proliferation of human bone marrow mesenchymal stem cells from older individuals.

This dataset provides supplemental material for a study on long-term particulate matter exposure and androgenetic alopecia risk, including additional exposure data and sensitivity analyses, but reports no new clinical results.

In this study, 12-Chloracetyl-PPD showed anti-cancer activity by inhibiting cancer cell viability and inducing apoptosis through reactive oxygen species production without harming normal cells.

This study found that DPCP immunotherapy effectively treats alopecia areata, identifying factors that influence treatment response and patient satisfaction, which may aid in standardizing the treatment for improved outcomes.

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

This study demonstrates that machine learning-assisted fabrication of PRP-incorporated microneedles effectively promotes hair regrowth in AGA mice, outperforming minoxidil and mitigating biosafety risks associated with synthetic materials.

This study observed that chronic and acute exposure to finasteride negatively impacted development, reproduction, and gene expression in Daphnia magna, highlighting the environmental risks of this pharmaceutical for freshwater ecosystems.

This study found that finasteride microemulsions significantly increased skin permeability in vitro, highlighting the potential for enhanced delivery of this drug through the skin.

This study found that after 24 weeks of DPCP treatment for alopecia areata, there was a significant increase in new capillaries and hair regrowth detectable by videocapillaroscopy.

Combining topical dutasteride with microneedling is more effective for hair growth than microneedling alone.

This study found that a lipid-based nanoparticle formulation with oleic acid for delivering dutasteride showed lower skin permeation compared to a formulation without oleic acid, indicating its potential for targeted dermal delivery.

In this case report, a 9-year-old boy with diffuse alopecia areata showed improvement with topical diphencyprone immunotherapy, suggesting it as a safe and effective treatment option in pediatric cases of alopecia areata resistant to other therapies.

In a study on wound healing, researchers described injectable POEGMA‐DA hydrogels as a promising non-toxic alternative to traditional wound closure methods, showing effective tissue adhesion and enhanced regeneration of skin structures in a mouse model without significant inflammation.

This study found that dexamethasone effectively suppressed DHEAS levels in women with elevated levels using much lower doses than previously thought, without significant adverse effects.